array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Tekla Life Sciences Investors"
["slug"]=>
string(38) "30be8-us-tekla-life-sciences-investors"
["logo"]=>
NULL
["description"]=>
string(523) "Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL."
["address_street"]=>
string(17) "2 Liberty Sq FL 9"
["address_place"]=>
string(6) "Boston"
["address_region"]=>
string(13) "Massachusetts"
["founding_date"]=>
string(10) "2000-01-26"
["website_domain"]=>
string(12) "teklacap.com"
["website_url"]=>
string(24) "https://www.teklacap.com"
["industry_codes"]=>
array(1) {
[0]=>
string(39) "Management Investment Offices, Open-End"
}
["employee_count"]=>
int(7)
["article_count"]=>
int(78)
}
["articles"]=>
array(4) {
[0]=>
array(7) {
["title_en"]=>
string(90) "Insider Buying: President Daniel Omstead Acquires 12,000 Shares of Tekla Life Sciences ..."
["snippet_en"]=>
string(160) "On September 20, 2023, President Daniel Omstead of Tekla Life Sciences Investors (NYSE:HQL) made a significant purchase of 12,000 shares of the company's stock."
["url"]=>
string(85) "https://finance.yahoo.com/news/insider-buying-president-daniel-omstead-090129980.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c4a0c45d-f201-4981-be22-137183d32e53"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-09-21"
["categories"]=>
array(4) {
[0]=>
string(11) "Acquisition"
[1]=>
string(16) "Share Repurchase"
[2]=>
string(12) "Stock Market"
[3]=>
string(14) "Issuing Shares"
}
}
[1]=>
array(7) {
["title_en"]=>
string(74) "Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program"
["snippet_en"]=>
string(39) "BOSTON--(BUSINESS WIRE)--Mar 16, 2023--"
["url"]=>
string(160) "https://www.bakersfield.com/ap/news/tekla-life-sciences-investors-announce-renewal-of-share-repurchase-program/article_79d4cb92-e0fa-56b8-a31c-e0308f47140b.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b0dd0532-f911-4f6c-87f6-b33f7d10be93"
["source"]=>
string(15) "bakersfield.com"
["publication_date"]=>
string(10) "2023-03-16"
["categories"]=>
array(1) {
[0]=>
string(16) "Share Repurchase"
}
}
[2]=>
array(7) {
["title_en"]=>
string(59) "Tekla Life Sciences Investors Announce Renewal of Share ..."
["snippet_en"]=>
string(189) "25-03-2021 · BOSTON, MA, March 25, 2021 – Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program."
["url"]=>
string(106) "https://www.teklacap.com/news/tekla-life-sciences-investors-announce-renewal-of-share-repurchase-program5/"
["image_url"]=>
NULL
["source"]=>
string(12) "teklacap.com"
["publication_date"]=>
string(10) "2021-03-25"
["categories"]=>
array(2) {
[0]=>
string(16) "Share Repurchase"
[1]=>
string(12) "Stock Market"
}
}
[3]=>
array(7) {
["title_en"]=>
string(74) "Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program"
["snippet_en"]=>
string(304) "Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July"
["url"]=>
string(136) "https://www.morningstar.com/news/business-wire/20230316005677/tekla-life-sciences-investors-announce-renewal-of-share-repurchase-program"
["image_url"]=>
NULL
["source"]=>
string(15) "morningstar.com"
["publication_date"]=>
NULL
["categories"]=>
array(2) {
[0]=>
string(16) "Share Repurchase"
[1]=>
string(12) "Stock Market"
}
}
}
["category_annotations"]=>
array(22) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(16)
}
[1]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(6)
}
[2]=>
array(2) {
["name"]=>
string(10) "Tax Havens"
["count"]=>
int(6)
}
[3]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(5)
}
[4]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(4)
}
[5]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(4)
}
[6]=>
array(2) {
["name"]=>
string(21) "Shareholders Feedback"
["count"]=>
int(4)
}
[7]=>
array(2) {
["name"]=>
string(16) "Share Repurchase"
["count"]=>
int(4)
}
[8]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(3)
}
[9]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(2)
}
[10]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(2)
}
[11]=>
array(2) {
["name"]=>
string(11) "Regulations"
["count"]=>
int(2)
}
[12]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(2)
}
[13]=>
array(2) {
["name"]=>
string(22) "Business Restructuring"
["count"]=>
int(2)
}
[14]=>
array(2) {
["name"]=>
string(20) "Corporate Governance"
["count"]=>
int(2)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(1)
}
[16]=>
array(2) {
["name"]=>
string(23) "Supply Chain Management"
["count"]=>
int(1)
}
[17]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(1)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(1)
}
[19]=>
array(2) {
["name"]=>
string(19) "Investment Requests"
["count"]=>
int(1)
}
[20]=>
array(2) {
["name"]=>
string(9) "Investors"
["count"]=>
int(1)
}
[21]=>
array(2) {
["name"]=>
string(20) "Business Development"
["count"]=>
int(1)
}
}
}
30be8-us-tekla-life-sciences-investors
Tekla Life Sciences Investors
Tekla Life Sciences Investors
Location
Massachusetts
Founded
2000-01-26
Website
https://www.teklacap.com
Articles
78 Articles
Category
Management Investment Offices, Open-End
Description
Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL.
On September 20, 2023, President Daniel Omstead of Tekla Life Sciences Investors (NYSE:HQL) made a significant purchase of 12,000 shares of the company's stock.
25-03-2021 · BOSTON, MA, March 25, 2021 – Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program.
Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.